secwatch.observer — SEC 8-K summary
======================================

Issuer:     PTC THERAPEUTICS, INC. (PTCT)
CIK:        0001070081
Form:       8-K
Filed at:   2025-02-27T23:59:59+00:00
Accession:  0001070081-25-000011
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PTC Therapeutics reports FY2024 revenue $807M above guidance; cash >$2B after Novartis deal
--------------------------------------------------------------------------------

- FY2024 total revenue $806.8M, exceeding guidance; net loss $363.3M vs $626.6M prior year.
- Cash and marketable securities $1.14B at Dec 31, 2024; >$2B after Jan 2025 Novartis PTC518 deal.
- Four NDAs accepted by FDA in 2024; sepiapterin PDUFA July 29, 2025, vatiquinone priority review Aug 19, 2025.
- FY2025 revenue guidance $600-800M; GAAP R&D+SG&A $805-835M; cash supports commercial and R&D plans.
- DMD franchise revenue $144M in Q4; Translarna $93.7M, Emflaza $50.5M; Evrysdi royalties $203.9M in FY2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1070081/000107008125000011/0001070081-25-000011-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1070081/000107008125000011/tmb-20250227x8k.htm
  HTML page:      https://secwatch.observer/filing/0001070081-25-000011

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer